Bevacizumab Pharmacology 

Bevacizumab
Bevacizumab
Humanized monoclonal antibody, angiogenesis inhibitor. anti neoplastic.
Humanized monoclonal antibody, angiogenesis inhibitor. anti neoplastic.
Bevacizumab is a recombinant humanized monoclonal antibody. It inhibits the biologic activity of human vascular endothelial growth factor (VEGF).Bevacizumab binds to VEGF and inhibits the interaction of VEGF to its receptors (VEGFR1 and VEGFR2). VEGF is an angiogenic growth factor that regulates vascular proliferation and permeability and inhibits apoptosis of new blood vessels. This may reduce tumor cell growth.In colorectal cancer patients, the Bevacizumab causes reduction of microvascular growth and inhibition of metastatic disease
progression.
Bevacizumab is a recombinant humanized monoclonal antibody. It inhibits the biologic activity of human vascular endothelial growth factor (VEGF).Bevacizumab binds to VEGF and inhibits the interaction of VEGF to its receptors (VEGFR1 and VEGFR2). VEGF is an angiogenic growth factor that regulates vascular proliferation and permeability and inhibits apoptosis of new blood vessels. This may reduce tumor cell growth.In colorectal cancer patients, the Bevacizumab causes reduction of microvascular growth and inhibition of metastatic disease
progression.
N/A
N/A
N/A
N/A
N/A
N/A
20days
20days